RxDoctor Payments Data

Scott Marquard, DO

Family Medicine · Glendale, AZNPI 1225399736

Payments from drug & device makers

$884in general payments, 2019–2025

Across 26 payments — averaging $33.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sirtex Medical Inc$617
  • Novo Nordisk$113
  • Sanofi-aventis U.S. LLC$35
  • Teva Pharmaceuticals USA, Inc.$26
  • AstraZeneca$25
  • GSK$16
  • plus $51 from 4 others

What the payments were for

  • Food & beverage$77387%
  • Education$11113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$884 in reported general payments places this provider in the 70th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$267,727
Medicare patients
347
Services billed
3,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin186$175,746
OzempicSemaglutide154$163,387
EliquisApixaban102$115,793
JanuviaSitagliptin Phosphate41$53,057
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$49,086
ProliaDenosumab26$43,975
FarxigaDapagliflozin Propanediol43$33,349
ShingrixVaricella-Zoster Ge/As01b/Pf106$23,524
TrulicityDulaglutide13$21,946
MounjaroTirzepatide17$18,636
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$18,129
Breo ElliptaFluticasone/Vilanterol33$18,104
XareltoRivaroxaban26$16,604
MyrbetriqMirabegron16$14,695
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$9,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$113$163,387154 claims
PfizerEliquis$11$115,793102 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta$16$99,696214 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$25$59,64088 claims
AmgenProlia$14$43,97526 claims
Lilly USA, LLCTrulicity, Mounjaro$11$40,58230 claims
Sanofi-aventis U.S. LLCLantus$35$3,09722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →